Understanding AAV Serotypes: How Capsid Diversity Shapes Gene Delivery

Adeno-associated virus, or AAV, has become one of the most widely used delivery platforms in gene therapy because it combines a relatively favorable safety profile with strong versatility across tissues and disease settings. One of the key reasons AAV has remained so adaptable is the existence of multiple serotypes, each defined by a distinct capsid with different biological behavior. These capsid differences influence how the vector binds to cells, where it distributes in vivo, how efficiently it transduces target tissues, and how it is recognized by the immune system. For that reason, serotype selection is not a minor formulation detail; it is a central strategic decision in AAV research and development.

What is an AAV serotype?

In the AAV field, the term serotype generally refers to a capsid-defined viral variant that can be distinguished by antigenic and structural properties. Although many AAV vectors share similar genome organization, changing the capsid can significantly alter vector behavior. Historically, AAV2 was the first serotype to be studied in depth and became the early benchmark for AAV vector development. As additional natural serotypes were identified, researchers recognized that different capsids could confer markedly different tropism and transduction profiles. This discovery helped transform AAV from a single vector platform into a broad delivery toolbox.

Why serotypes matter in gene therapy

Serotype matters because the capsid plays a decisive role in the earliest steps of transduction, including attachment to the cell surface, uptake, intracellular trafficking, and nuclear delivery. In practical terms, that means the same therapeutic cassette can perform very differently depending on which capsid is used to package it. Some serotypes are widely associated with muscle-directed delivery, some are favored for liver applications, and others are used in CNS or ocular settings. At the same time, these are best understood as general tendencies rather than absolute rules, because actual performance depends on route of administration, species, age, dose, target cell type, and study design.

Major natural serotypes and their commonly recognized profiles

AAV1

AAV1 is widely associated with strong transduction in skeletal muscle and has also been used in cardiac and CNS studies. It binds sialylated glycans, and its biology overlaps partly with AAV6. In practice, AAV1 is often considered when muscle-directed delivery is a priority, especially for local or regional administration.

AAV2

AAV2 is the canonical serotype in the field and remains the historical benchmark. It is classically associated with heparan sulfate proteoglycan binding and has been extensively used for retinal, CNS, and proof-of-concept studies because its molecular biology was characterized early and deeply. Clinically, AAV2 has special significance because Luxturna is based on an AAV2 vector, making AAV2 the serotype most directly tied to the first FDA-approved in vivo AAV gene therapy in the United States.

AAV3

AAV3 has historically received less attention than AAV2, AAV8, or AAV9, but it has shown utility in some liver and cancer-related vectorology contexts and remains relevant in comparative capsid biology. It is best viewed as a serotype of mechanistic and niche translational interest rather than the dominant default for systemic clinical delivery.

AAV4

AAV4 is notable for a tropism pattern distinct from the more commonly used systemic serotypes. It has often been associated with ependymal and certain CNS-adjacent cell populations rather than broad systemic utility. Recent comparative work also suggests unusual biodistribution features, including relative liver detargeting in some experimental settings, underscoring that less commonly used serotypes may still offer strategic advantages in specialized applications.

AAV5

AAV5 is a clinically important serotype, especially in liver-directed gene therapy. It is commonly described as using sialic acid-related attachment interactions and depending on AAVR for entry. AAV5-based or AAV5-related vectors have been used in approved hemophilia gene therapies, which is one reason this serotype remains highly relevant in translational development despite not being as ubiquitous in basic research as AAV2.

AAV6

AAV6 is closely related to AAV1 and is also associated with sialic acid binding. It has shown value in muscle, airway, and some hematopoietic or ex vivo transduction contexts. AAV6 is often discussed as a strong performer in settings where AAV1-like biology is desirable but with somewhat different entry behavior or neutralization characteristics.

AAV7 and AAV8

AAV8 became one of the most important serotypes for liver-directed gene transfer because of its robust hepatotropic behavior in many preclinical and translational settings. It is frequently cited as a leading liver vector and has heavily influenced both preclinical design and clinical development strategies. Recent human liver work also supports efficient AAV8 functional transduction, though the exact cell-type distribution in human tissue is more nuanced than a simple “hepatocyte only” narrative.

AAV9

AAV9 is one of the most influential serotypes in the field because of its strong systemic performance and its ability, under some conditions, to access the central nervous system after intravenous delivery, especially in neonatal or juvenile settings. It binds terminal galactose-containing glycans and has become a cornerstone of neuromuscular and CNS gene therapy development. The clinical importance of AAV9 is highlighted by approved products such as onasemnogene abeparvovec, listed by FDA under the trade name ITVISMA, and by the broader use of AAV9-like biology in systemic pediatric gene transfer. That said, CNS access by AAV9 is not uniform across species or ages, and rodent findings should not be overgeneralized directly to humans.

Serotypes in approved gene therapies

FDA’s current list of licensed cellular and gene therapy products includes multiple AAV-based therapies, illustrating that no single serotype dominates all indications. Luxturna uses AAV2 for inherited retinal disease, while liver- and systemic-delivery programs have relied on other capsids including AAV5 and AAV9-related vectors. FDA’s approved list currently includes products such as Luxturna, HEMGENIX, ROCTAVIAN, ELEVIDYS, BEQVEZ, KEBILIDI, and ITVISMA, reflecting the central role of AAV platforms in commercial gene therapy. This clinical diversity reinforces a key principle: different indications require different capsid solutions.

Tissue tropism: useful rules of thumb, but not absolutes

A common shorthand in the field is that AAV2 is favored for retina and localized delivery, AAV1/AAV6 for muscle, AAV8 for liver, and AAV9 for systemic CNS or neuromuscular applications. This summary is directionally useful, but it is still a simplification. Real-world performance depends on the route of administration, species, assay endpoint, and target cell type within the organ. For example, liver-directed performance observed in mice may not map cleanly to primates or humans, and certain capsids that cross the blood-brain barrier efficiently in one mouse strain may perform poorly in another strain or in nonhuman primates. For that reason, capsid selection should be grounded in target-relevant data rather than textbook assumptions alone.

The importance of species dependence

One of the biggest lessons from the last decade is that AAV serotype performance is species dependent. This is particularly important for CNS-targeting capsids and for hepatotropic vectors. Differences in receptor abundance, glycan presentation, intracellular trafficking, and immune background can produce major shifts in biodistribution. Recent comparative studies explicitly show significant interspecies and even inter-strain variability in AAV tropism. Therefore, the phrase “this serotype targets X tissue” should always be qualified with “in this model and by this route.”

Seroprevalence and neutralizing antibodies

Pre-existing anti-AAV immunity remains one of the largest translational barriers in serotype selection. Neutralizing antibodies can block transduction, exclude patients from systemic trials, and complicate re-dosing. The exact prevalence varies with serotype, geography, age, assay method, and study population, but the literature consistently shows that anti-AAV antibodies are common in humans. AAV2 often shows relatively high pre-existing neutralization rates in many cohorts, while seroprevalence differs across other serotypes such as AAV5, AAV8, and AAV9. Because results are assay dependent, programs should avoid assuming that one published prevalence figure applies universally across patient populations.

Safety does not depend only on serotype, but serotype contributes

AAV is often described as having a favorable safety profile compared with many other viral delivery systems, and that general statement remains fair. However, current reviews and recent mechanistic studies make clear that safety concerns can include immune responses, hepatotoxicity, neurotoxicity, thrombotic microangiopathy, genotoxicity concerns, and innate inflammatory responses. Serotype matters because biodistribution and cell-type entry influence where vector genomes accumulate and which tissues bear dose-related toxicologic burden. In other words, capsid choice is a safety decision as much as an efficacy decision.

Natural serotypes versus engineered capsids

Natural serotypes remain foundational, but many of the most exciting current advances come from capsid engineering. Rational design, peptide insertion, DNA shuffling, and directed evolution have all been used to enhance transduction efficiency, alter tropism, evade antibodies, or reduce off-target uptake. Engineered capsids can outperform natural serotypes in particular organs, but they also raise additional translational questions about manufacturability, species transferability, and immunologic novelty. In that sense, natural serotypes are no longer the endpoint of AAV vectorology; they are the starting framework from which next-generation vectors are built.

Practical principles for choosing an AAV serotype

A rational serotype-selection strategy should begin with the target biology rather than with market popularity. The first questions should be: Which cells must be transduced? By what route will the vector be delivered? In which species and age group will performance be evaluated? What level of pre-existing immunity is expected in the intended patient population? And what safety liabilities arise from systemic exposure to non-target tissues? In many programs, the optimal answer is not the serotype with the highest raw transduction in vitro, but the one with the best balance of potency, manufacturability, tissue selectivity, immunologic compatibility, and clinical precedent.

Outlook

The AAV serotype field has evolved from a handful of naturally occurring capsids into a sophisticated vector-selection discipline that integrates structural biology, receptor biology, comparative animal studies, human tissue data, immunology, and clinical translation. Natural serotypes such as AAV1, AAV2, AAV5, AAV6, AAV8, and AAV9 still define much of the conceptual framework of the field, but the future will increasingly depend on engineered capsids optimized for specific tissues and patient populations. The central lesson is that serotype is not merely a label on a vector; it is a core determinant of efficacy, distribution, immune recognition, and safety. Careful serotype selection, combined with target-relevant validation, remains one of the most decisive steps in successful AAV gene therapy development.

At PackGene, we support AAV programs across discovery, preclinical development, and translation with integrated capabilities spanning vector design and construction, AAV packaging and production, analytical testing, serotype screening, and capsid engineering. PackGene’s current AAV service portfolio includes research-grade AAV packaging with access to 70+ serotypes, broader AAV production services for research and GMP applications, dedicated AAV analytical testing, and capsid engineering support for teams pursuing next-generation delivery strategies. Together, these capabilities are designed to help researchers move from serotype selection to experimentally validated vector solutions with greater speed and confidence